Diabeloop, a company focused on collective intelligence

“At Diabeloop, there are 2 core elements that motivate people on a daily-basis. The first one is teamwork. We feel great pride when we work together to accomplish challenging goals. The second one is about seeing our impact on people living with Type 1 diabetes. When they say: “It’s extraordinary, you have changed my life”, it gives us pride, energy and motivation to continue. That is why we get up every morning!” – Erik Huneker, co-founder and CEO of Diabeloop.

Project initiation

Dr. Guillaume Charpentier, diabetologist and president of the Center of Excellence for Research and Treatment of Diabetes (CERITD), initiated the medical research project.

Creation of Diabeloop

Diabeloop was created by Dr. Guillaume Charpentier and Erik Huneker. Closely linked to the CEA-Leti.

Clinical studies and first round of funding

  • End of the fourth round of SP7 clinical trials, a pivotal study completed in partnership with 12 university hospitals, to ensure the safety and efficacy of the DBLG1 System. 
  • First round of funding of 13.5 million euros.

The DBLG1 obtained CE marking

  • In November 2018, the first medical device developed by Diabeloop received CE marking, marketing authorization in Europe. 
  • Opening of the office in Paris.

Record breaking second round of funding in therapeutic artificial intelligence

 

  • Conclusion of a Record-Breaking European Fundraising Effort of 31 million euros in the area of therapeutic artificial intelligence. 

 

  • Submission of the DBLG1 System to the French reimbursement agreement. 
  • Clinical trials performed in children with Type 1 diabetes and adults with highly unstable diabetes (labile diabetes).

International perspectives

  • Advanced discussions with German health insurers to make our DBLG1 algorithm available in the German market.
  • Inauguration of our new headquarters in Grenoble (BHT2).
2011
2015
2017
2018
2019
2020
2011
2015
2017
2018
2019
2020

Project initiation

Dr. Guillaume Charpentier, diabetologist and president of the Center of Excellence for Research and Treatment of Diabetes (CERITD), initiated the medical research project.

Our ecosystem

The international ambition of a diabetes medtech

In November 2018, Diabeloop’s first medical device, the DBLG1, obtained CE marking, a marketing authorization for most of Europe. 

In 2019, the company submitted the DBLG1 System to French reimbursement agreement. 

In Germany, a market particularly interested by new technologies, Diabeloop is in the midst of conversations with health insurers. 

In the medium term, we are planning a progressive commercial launch in a majority of European countries.

Technological

CEA-Leti is an internationally-renowned tech research institute, and specializes in micro and nano-technologies. As a long-time partner of Diabeloop, it also shares a research laboratory with the company.

Medical

CERITD (research team of diabetologists), managed by Dr. Guillaume Charpentier, is a non-profit organization dedicated to diabetes research and treatment.

Medical centres

Since 2010, Diabeloop has been conducting clinical trials, in which more than 300 patients have been involved, in collaboration with French and european university hospitals.

Our partners and supporters

  • Technological
  • Medical
  • Medical centres

CEA-Leti is an internationally-renowned tech research institute, and specializes in micro and nano-technologies. As a long-time partner of Diabeloop, it also shares a research laboratory with the company.

Diabeloop's management

  • Catherine Dunand, President of the board
  • Pr. Pierre-Yves Benhamou, Chief Medical Officer
  • Erik Huneker, co-founder and CEO

 

Diabeloop Supporters